Cargando…
Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer
BACKGROUND: Argonaute-2 (Ago2) is an essential component of microRNA biogenesis implicated in tumourigenesis. However Ago2 expression and localisation in breast cancer remains undetermined. The aim was to define Ago2 expression (mRNA and protein) and localisation in breast cancer, and investigate as...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642579/ https://www.ncbi.nlm.nih.gov/pubmed/31324173 http://dx.doi.org/10.1186/s12885-019-5884-x |
_version_ | 1783437005163593728 |
---|---|
author | Casey, M.C. Prakash, A. Holian, E. McGuire, A. Kalinina, O. Shalaby, A. Curran, C. Webber, M. Callagy, G. Bourke, E. Kerin, M. J. Brown, J. A. |
author_facet | Casey, M.C. Prakash, A. Holian, E. McGuire, A. Kalinina, O. Shalaby, A. Curran, C. Webber, M. Callagy, G. Bourke, E. Kerin, M. J. Brown, J. A. |
author_sort | Casey, M.C. |
collection | PubMed |
description | BACKGROUND: Argonaute-2 (Ago2) is an essential component of microRNA biogenesis implicated in tumourigenesis. However Ago2 expression and localisation in breast cancer remains undetermined. The aim was to define Ago2 expression (mRNA and protein) and localisation in breast cancer, and investigate associations with clinicopathological details. METHODS: Ago2 protein was stained in breast cancer cell lines and tissue microarrays (TMAs), with intensity and localization assessed. Staining intensity was correlated with clinicopathological details. Using independent databases, Ago2 mRNA expression and gene alterations in breast cancer were investigated. RESULTS: In the breast cancer TMAs, 4 distinct staining intensities were observed (Negative, Weak, Moderate, Strong), with 64.2% of samples stained weak or negatively for Ago2 protein. An association was found between strong Ago2 staining and, the Her2 positive or basal subtypes, and between Ago2 intensity and receptor status (Estrogen or Progesterone). In tumours Ago2 mRNA expression correlated with reduced relapse free survival. Conversely, Ago2 mRNA was expressed significantly lower in SK-BR-3 (HER2 positive) and BT-20 (Basal/Triple negative) cell lines. Interestingly, high levels of Ago2 gene amplification (10–27%) were observed in breast cancer across multiple patient datasets. Importantly, knowledge of Ago2 expression improves predictions of breast cancer subtype by 20%, ER status by 15.7% and PR status by 17.5%. CONCLUSIONS: Quantification of Ago2 improves the stratification of breast cancer and suggests a differential role for Ago2 in breast cancer subtypes, based on levels and cellular localisation. Further investigation of the mechanisms affecting Ago2 dysregulation will reveal insights into the molecular differences underpinning breast cancer subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5884-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6642579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66425792019-07-29 Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer Casey, M.C. Prakash, A. Holian, E. McGuire, A. Kalinina, O. Shalaby, A. Curran, C. Webber, M. Callagy, G. Bourke, E. Kerin, M. J. Brown, J. A. BMC Cancer Research Article BACKGROUND: Argonaute-2 (Ago2) is an essential component of microRNA biogenesis implicated in tumourigenesis. However Ago2 expression and localisation in breast cancer remains undetermined. The aim was to define Ago2 expression (mRNA and protein) and localisation in breast cancer, and investigate associations with clinicopathological details. METHODS: Ago2 protein was stained in breast cancer cell lines and tissue microarrays (TMAs), with intensity and localization assessed. Staining intensity was correlated with clinicopathological details. Using independent databases, Ago2 mRNA expression and gene alterations in breast cancer were investigated. RESULTS: In the breast cancer TMAs, 4 distinct staining intensities were observed (Negative, Weak, Moderate, Strong), with 64.2% of samples stained weak or negatively for Ago2 protein. An association was found between strong Ago2 staining and, the Her2 positive or basal subtypes, and between Ago2 intensity and receptor status (Estrogen or Progesterone). In tumours Ago2 mRNA expression correlated with reduced relapse free survival. Conversely, Ago2 mRNA was expressed significantly lower in SK-BR-3 (HER2 positive) and BT-20 (Basal/Triple negative) cell lines. Interestingly, high levels of Ago2 gene amplification (10–27%) were observed in breast cancer across multiple patient datasets. Importantly, knowledge of Ago2 expression improves predictions of breast cancer subtype by 20%, ER status by 15.7% and PR status by 17.5%. CONCLUSIONS: Quantification of Ago2 improves the stratification of breast cancer and suggests a differential role for Ago2 in breast cancer subtypes, based on levels and cellular localisation. Further investigation of the mechanisms affecting Ago2 dysregulation will reveal insights into the molecular differences underpinning breast cancer subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5884-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-19 /pmc/articles/PMC6642579/ /pubmed/31324173 http://dx.doi.org/10.1186/s12885-019-5884-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Casey, M.C. Prakash, A. Holian, E. McGuire, A. Kalinina, O. Shalaby, A. Curran, C. Webber, M. Callagy, G. Bourke, E. Kerin, M. J. Brown, J. A. Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer |
title | Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer |
title_full | Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer |
title_fullStr | Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer |
title_full_unstemmed | Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer |
title_short | Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer |
title_sort | quantifying argonaute 2 (ago2) expression to stratify breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642579/ https://www.ncbi.nlm.nih.gov/pubmed/31324173 http://dx.doi.org/10.1186/s12885-019-5884-x |
work_keys_str_mv | AT caseymc quantifyingargonaute2ago2expressiontostratifybreastcancer AT prakasha quantifyingargonaute2ago2expressiontostratifybreastcancer AT holiane quantifyingargonaute2ago2expressiontostratifybreastcancer AT mcguirea quantifyingargonaute2ago2expressiontostratifybreastcancer AT kalininao quantifyingargonaute2ago2expressiontostratifybreastcancer AT shalabya quantifyingargonaute2ago2expressiontostratifybreastcancer AT curranc quantifyingargonaute2ago2expressiontostratifybreastcancer AT webberm quantifyingargonaute2ago2expressiontostratifybreastcancer AT callagyg quantifyingargonaute2ago2expressiontostratifybreastcancer AT bourkee quantifyingargonaute2ago2expressiontostratifybreastcancer AT kerinmj quantifyingargonaute2ago2expressiontostratifybreastcancer AT brownja quantifyingargonaute2ago2expressiontostratifybreastcancer |